|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities available-for-sale | ||||||||||||||||||||
| Accounts receivables, net of allowance for doubtful accounts of $0 and $12,313 at September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Total accounts receivables, net of allowance for doubtful accounts of $0 and $12,313 at September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid manufacturing | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other assets, net of allowance for doubtful accounts of $10,970 at September 30, 2025 | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued research and development | ||||||||||||||||||||
| CEPI accrual long-term (Note 6) | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Convertible Notes, current portion, net of debt discount of $135 at September 30, 2025 (Note 7) | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible Notes, net of debt discount of $4,701 and $1,646 at March 31, 2025 and December 31, 2024, respectively (Note 7) | ||||||||||||||||||||
| Convertible Notes, net of debt discount of $4,034 and $1,646 at September 30, 2025 and December 31, 2024, respectively (Note 7) | ||||||||||||||||||||
| Long-term portion of lease liabilities | ||||||||||||||||||||
| CEPI accrual long-term (Note 6) | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock: $0.001 par value, 5,000 shares authorized at September 30, 2025 and December 31, 2024; zero shares outstanding at September 30, 2025 and December 31, 2024 | ||||||||||||||||||||
| Common stock: $0.001 par value, 278,000 shares authorized at September 30, 2025 and December 31, 2024; 117,364 shares and 125,450 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
